NCT00637845View on ClinicalTrials.gov

Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)

PHASE4CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions
HeartburnGastroesophageal Reflux Disease
Interventions
DRUG

Esomeprazole Magnesium

40mg once daily

DRUG

Lansoprazole

30mg twice daily

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00637845 - Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) | Biotech Hunter | Biotech Hunter